Letter to the Editor

Letter to the Editor

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

July 3, 2023

Bénédicte Nobile, PharmD, PhD, and Philippe Courtet, MD, PhD, continue the discussion of potentially increased suicidal risk with daridorexant, a new hypnotic.

Letter to the Editor

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.

Letter to the Editor

Comment on Palinacousis or Auditory Perseverations and COVID-19 Vaccination

June 27, 2023

In this letter to the editor, Amnuay Kleebayoon, PhD, and Viroj Wiwanitkit, MD, comment on a report published recently in the PCC.

Letter to the Editor

Varenicline Use for Cocaine Dependence

May 30, 2023

In this letter to the editor, Abhishek Gupta, MBBS, reviews the latest research on the use of varenicline in cocaine dependence.

Letter to the Editor

Zoom Dysmorphia and Body Dysmorphic Disorder

April 27, 2023

In this letter to the editor, Tomás Teodoro, MD, MSc, comments on a report recently published in the PCC.

Letter to the Editor

Neuropsychiatric Manifestations of Mpox

April 18, 2023

Rujittika Mungmunpuntipantip, PhD, and Viroj Wiwanitkit, MD, comment on a report recently published in the PCC.